Hidaka, Saitama
Recruiting
A Study to Assess the Safety, Tolerability, Efficacy, and Drug Levels of BMS-986369 (Golcadomide) in Participants With Relapsed or Refractory T-cell Lymphomas in Japan (GOLSEEK-3)
Phase
1/2Span
360 weeksSponsor
Bristol-Myers SquibbHidaka, Saitama
Recruiting
Pembrolizumab and Bevacizumab With Chemotherapy Followed by Pembrolizumab, Bevacizumab and Olaparib in Recurrent Ovarian Cancer
Phase
2Span
137 weeksSponsor
Kosei Hasegawa, MD, PhDHidaka, Saitama
Recruiting
Phase 1/2 Study of REGN5458 in Adult Patients With Relapsed or Refractory Multiple Myeloma
Phase
1/2Span
701 weeksSponsor
Regeneron PharmaceuticalsHidaka, Saitama
Recruiting
A Study to Assess the Anti-Tumor Activity and Safety of Odronextamab in Adult Patients With B-cell Non-Hodgkin Lymphoma Who Have Been Previously Treated With Other Cancer Therapies
Phase
2Span
528 weeksSponsor
Regeneron PharmaceuticalsHidaka, Saitama
Recruiting
Product Surveillance Registry
Phase
N/ASpan
1466 weeksSponsor
MedtronicHidaka, Saitama
Recruiting
Hidaka, Saitama
Recruiting
Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)
Phase
3Span
1302 weeksSponsor
Merck Sharp & Dohme LLCHidaka, Saitama
Recruiting
A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid Tumor
Phase
1/2Span
425 weeksSponsor
Eisai Inc.Hidaka, Saitama
Recruiting
ONO-4538 Phase II Rollover Study (ONO-4538-98)
Phase
2Span
329 weeksSponsor
Ono Pharmaceutical Co. LtdHidaka, Saitama
Recruiting
1-10 of 22